This trial is active, not recruiting.

Condition acute heart failure
Treatments rlx030, placebo
Phase phase 3
Sponsor Novartis Pharmaceuticals
Start date October 2013
End date January 2017
Trial size 6505 participants
Trial identifier NCT01870778, 2013-001498-25, CRLX030A2301


The purpose of the study to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
(Placebo Comparator)
patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
Patients will receive continuous intravenous infusion of serelaxin for 48 hours.
intravenous infusion

Primary Outcomes

Time to confirmed cardiovascular (CV) death during the follow-up period of 180 days
time frame: From baseline to 180 days
Time to worsening of heart failure (WHF) through Day 5 (considering death in the 5-day)
time frame: From Baseline to Day 5

Secondary Outcomes

Time to all-cause death through Day 180
time frame: From baseline to 180 days
Length of total hospital stay (LOS) during the index acute heart failure (AHF) hospitalization
time frame: From baseline to 180 days
Time to first occurrence of the composite endpoint of CV death or rehospitalization due to heart failure or renal failure through day 180
time frame: From baseline to 180 days
Length of Intensive Care Unit (ICU) and/or Coronary care unit (CCU) stay for the index AHF hospitalization
time frame: From baselint to 180 days
Change from baseline in congestive signs and symptoms of heart failure through Day 5
time frame: From baseline to Day 5
Change from baseline in selected biomarkers from baseline through Day 14 in a subset
time frame: From baseline to Day 14
Number of patients reported with total adverse events, serious adverse events and death
time frame: For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.

Eligibility Criteria

Male or female participants at least 18 years old.

Key Inclusion Criteria: - Male or female 18 years of age, with body weight ≤160 kg - Hospitalized for AHF with anticipated requirment of IV therapy for at least 48 hours; AHF is defined as including all of the following measured at any time between presentation (including the emergency department) and the end of screening: - Persistent dyspnea at rest or with minimal exertion - Pulmonary congestion on chest radiograph - BNP ≥500 pg/mL or NT-proBNP ≥2000 pg/mL; for patients ≥ 75 years of age or with current atrial fibrillation (at the time of randomization), BNP ≥ 750 pg/mL or NT-proBNP ≥ 3,000 pg/mL - Systolic BP ≥125 mmHg at the start and at the end of screening - Able to be randomized within 16 hours from presentation to the hospital, including the emergency department - Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode. Key Exclusion Criteria: - Dyspnea primarily due to non-cardiac causes - Known history of respiratory disorders requiring the daily use of IV or oral steroids (does not include inhaled steroids); need for intubation or the current use of IV or oral steroids for COPD - Temperature >38.5°C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment - Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment. - AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of >130 beats per minute - Patients with severe renal impairment defined as pre-randomization eGFR < 25 mL/min/1.73m2 calculated using the sMDRD equation, and/or those receiving current or planned dialysis or ultrafiltration - Patients with hematocrit <25%, or a history of blood transfusion within the 14 days prior to screening, or active life-threatening GI bleeding. - Known hepatic impairment (as evidenced by total bilirubin > 3 mg/dL, or increased ammonia levels, if performed) or history of cirrhosis with evidence of portal hypertension such as varices. - Significant, uncorrected, left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm2 or mean gradient >40 mmHg on prior or current echocardiogram), and severe mitral stenosis - Severe aortic insufficiency or severe mitral regurgitation for which surgical or percutaneous intervention is indicated. - Documented, prior to or at the time of randomization, restrictive amyloid myocardiopathy, OR acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (does NOT include restrictive mitral filling patterns seen on Doppler echocardiographic assessments of diastolic function).

Additional Information

Official title A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients
Description This Phase IIIb outcome study in AHF patients is designed as a multicenter, randomized, double-blind, placebo-controlled, event-driven study in order to assess the efficacy, safety and tolerability of intravenous infusion of serelaxin or placebo. The AHF patients randomized to either serelaxin or placebo in the study will be followed for a period of 180 days, and are required to receive standard-of-care background HF management during both the index hospitalization and post discharge according to regional or local guidelines/institutional standards.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Novartis.